Pim-1 kinase as cancer drug target: An update | Zendy

YERNAR TURSYNBAY | Zendy; Jinfu Zhang | Zendy; Zhi Li | Zendy; Tursonjan Tokay | Zendy; Zhaxybay Zhumadilov | Zendy; Denglong Wu | Zendy; Yingqiu Xie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pim-1 kinase as cancer drug target: An update

Author(s) -

YERNAR TURSYNBAY,

Jinfu Zhang,

Zhi Li,

Tursonjan Tokay,

Zhaxybay Zhumadilov,

Denglong Wu,

Yingqiu Xie

Publication year - 2015

Publication title -

biomedical reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.607

H-Index - 25

eISSN - 2049-9442

pISSN - 2049-9434

DOI - 10.3892/br.2015.561

Subject(s) - biology , cancer , kinase , cancer research , cancer cell , cell cycle , pim1 , metastasis , oncogene , microbiology and biotechnology , phosphorylation , serine , genetics

Proviral integration site for Moloney murine leukemia virus-1 (Pim-1) is a serine/threonine kinase that regulates multiple cellular functions such as cell cycle, cell survival, drug resistance. Aberrant elevation of Pim-1 kinase is associated with numerous types of cancer. Two distinct isoforms of Pim-1 (Pim-1S and Pim-1L) show distinct cellular functions. Pim-1S predominately localizes to the nucleus and Pim-1L localizes to plasma membrane for drug resistance. Recent studies show that mitochondrial Pim-1 maintains mitochondrial integrity. Pim-1 is emerging as a cancer drug target, particularly in prostate cancer. Recently the potent new functions of Pim-1 in immunotherapy, senescence bypass, metastasis and epigenetic dynamics have been found. The aim of the present updated review is to provide brief information regarding networks of Pim-1 kinase and focus on its recent advances as a novel drug target.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research